114 related articles for article (PubMed ID: 28561693)
1. Age and Sex in Non-Hodgkin Lymphoma Therapy: It's Not All Created Equal, or Is It?
Pfreundschuh M
Am Soc Clin Oncol Educ Book; 2017; 37():505-511. PubMed ID: 28561693
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
3. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
4. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
Cohen JB; Ruppert AS; Heerema NA; Andritsos LA; Jones JA; Porcu P; Baiocchi R; Christian BA; Byrd JC; Flynn J; Penza S; Devine SM; Blum KA
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):278-285.e1. PubMed ID: 25660723
[TBL] [Abstract][Full Text] [Related]
5. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
Cohen JB; Han X; Jemal A; Ward EM; Flowers CR
Cancer; 2016 Aug; 122(15):2356-63. PubMed ID: 27153197
[TBL] [Abstract][Full Text] [Related]
6. Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.
Shah BK; Khanal A
Anticancer Res; 2015 Jun; 35(6):3437-40. PubMed ID: 26026107
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
8. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Smedby KE; Hjalgrim H
Semin Cancer Biol; 2011 Nov; 21(5):293-8. PubMed ID: 21945518
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
[TBL] [Abstract][Full Text] [Related]
11. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
14. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
15. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
Papin A; Le Gouill S; Chiron D
Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
[TBL] [Abstract][Full Text] [Related]
16. Autotransplantation for mantle cell lymphoma.
Vose JM
Cancer J; 2012; 18(5):427-31. PubMed ID: 23006947
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
Itoh K; Igarashi T; Irisawa H; Aotsuka N; Masuda S; Utsu Y; Tsujimura H; Tsukasaki K; Wakita H
Leuk Lymphoma; 2018 Jul; 59(7):1606-1613. PubMed ID: 29081255
[TBL] [Abstract][Full Text] [Related]
18. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
Rummel MJ; Chow KU; Jäger E; Leimer L; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
Leuk Lymphoma; 1999 Sep; 35(1-2):129-38. PubMed ID: 10512170
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Nasopharyngeal Lymphoma in the United States: A Population-Based Analysis of 1119 Cases.
Han AY; Kuan EC; Alonso JE; Badran KW; St John MA
Otolaryngol Head Neck Surg; 2017 May; 156(5):870-876. PubMed ID: 28322119
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]